Hemostemix Inc. (CVE:HEM – Get Free Report) shares rose 25% on Friday . The company traded as high as C$0.08 and last traded at C$0.08. Approximately 101,000 shares traded hands during mid-day trading, an increase of 3% from the average daily volume of 98,140 shares. The stock had previously closed at C$0.06.
Hemostemix Stock Performance
The stock’s 50 day simple moving average is C$0.07 and its two-hundred day simple moving average is C$0.06. The firm has a market capitalization of C$5.23 million, a PE ratio of -3.00 and a beta of 0.15.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- How to Calculate Return on Investment (ROI)
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
- What is the Shanghai Stock Exchange Composite Index?
- China’s EV Rally: Should Investors Chase, Avoid, or Buy the Dip?
- Stock Splits, Do They Really Impact Investors?
- MarketBeat Week in Review – 10/7 – 10/11
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.